Press Releases

Brenus Pharma presents promising preclinical results that extrapolate to human diseases at important international conferences These communications focus on the preclinical validation of new developments of the STC platform's first product, STC-1010, targeting first-line colorectal cancer. Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: “After we tested the STC product on colorectal cancer models in syngeneic immunoco

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has completed the enrollment of 1,000 participants across two studies as part of its ongoing clinical program to evaluate the long-term effectiveness of AspyreRxTM (formerly BT-001). AspyreRx received FDA authorization in July 2023 as the first PDT to deliver Cognitive Behavioral Therapy (CBT) to treat adults with type 2 diabetes (T2D

Today, the U.S. Food and Drug Administration is taking steps to help further accelerate the development of novel drug and biological products for rare diseases. The agency is announcing the opportunity for a limited number of sponsors to participate in a pilot program allowing for more frequent communication with FDA staff to provide a mechanism for addressing clinical development issues. "We hope the insight gained from this pilot will provide information on how best to facili

Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab (trade name: 开坦尼®), and RemeGen's first domestically developed antibody-drug conjugate (ADC) injection, Disitamab Vedotin (trade name: 爱地希®) in combination therapy. The collaboration will also initiate a phase II clinical study for gastric

Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care, a company developing upright patient positioning systems for radiation therapy. The goal of the partnership between the three

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®. The objective of the study is to compare ADL018 and XOLAIR® in terms of efficacy, safety, tolerability, and immunogenicity in patients with chronic idiopathic/spontaneous urticaria (CSU) who remain symptomatic on H1 antihistamine treatment. The study is e

A new event for global pharma will launch in 2024 with CPHI Middle East opening at the Riyadh Exhibition and Convention Center Malham, Saudi Arabia (10-12 December, 2024). The newly launched event will include an exhibition and conference and is being opened to help both regional and international pharma companies partner in one of the world’s fastest developing and growing pharma hubs. Saudi Arabia alone is predicted to grow at nearly 10% annually – reaching $19bn in 20

The life science group Sartorius and UK-based startup SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for biopharmaceutical drugs. Nanoparticles are small polymer or lipid capsules that act as carriers to deliver active agents to the target cells. As part of the cooperation, Sartorius will invest up to 3.5 million British pounds in a minority shareholding in SPARTA Biodiscov

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, is set to unveil its extensive range of excipients for moisture protection – including three new product grades – at CPHI Barcelona next month. The versatile portfolio offers enhanced stability and moisture protection for sensitive formulations, as well as providing pharmaceutical and nutraceutical manufacturers with a comprehensive range of low water activit

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform. The suite of new xGen NGS tools comprised of adapters, primers, and universal blockers can support a wide range of applications, including DNA, RNA and methylation sequencing workflows, as well as IDT’s prov